Therapeutic Strategies against Ebola Virus Infection.
Viruses
; 14(3)2022 03 11.
Article
em En
| MEDLINE
| ID: mdl-35336986
ABSTRACT
Since the 2014-2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença pelo Vírus Ebola
/
Vacinas contra Ebola
/
Ebolavirus
/
Epidemias
Limite:
Humans
Idioma:
En
Revista:
Viruses
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Taiwan